信州大学HOMEENGLISH交通・キャンパス案内

研究者総覧研究者総覧

研究者、研究内容などで検索
項目別検索はこちら

市山 崇史  イチヤマ タカシ

教員組織電話番号
教育組織医学部附属病院 集中治療部FAX番号
職名助教(診療)メールアドレス
住所〒390-8621 長野県松本市旭3-1-1ホームページURL

プロフィール

学歴
出身大学院
2017 , 信州大学 , 医学系 内科学1教室

取得学位
博士(医学) , 信州大学

研究活動業績

研究業績(著書・
発表論文等)
論文
Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution
Respirory Investigation,60(4):604-606 2022(Jun.)
Author:Takashi Ichiyama, Masamichi Komatsu, Yosuke Wada, Masayuki Hanaoka
Abstract:Many drugs have been marketed for treating coronavirus disease 2019 (COVID-19) infection, the disease that has caused a worldwide pandemic. However, in reported clinical trials, almost 30% of patients with COVID-19 did not show any health improvement. The 28-day survival rate was 69.5% when patients who required highflow oxygen therapy (HFNC), ventilation, and extracorporeal membrane oxygenation (ECMO) management were treated with remdesivir. The mortality rate of patients receiving 6 mg dexamethasone was 27%, and that of patients treated with tocilizumab and steroids was 31%. These results are unsatisfactory, and treatment for patients with severe respiratory failure has not yet been established. In our institution, we used remdesivir, methylprednisolone (mPSL) pulse therapy, and tocilizumab in 20 patients with COVID-19 whose PaO2/FIO2 (P/F) ratio was <200, and obtained good results for this combination therapy without any adverse events. In this study, we report the possible efficacy and safety of this treatment.


Effects of Subtype-selective E Prostanoid Receptor Agonists on Bleomycin-induced Pulmonary Fibrosis in Rats
信州医学雑誌,67(3):183-195 2019(Jun.)
Author:Ichiyama T, Yamamoto H, Hongo K